Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Stanford University

Status: Enrolling

Conditions: Head and Neck Cancers; Lip Cancer; Lung Cancer; Lip Neoplasms; Head and Neck Cancer

Treatments: Procedure: Phlebotomy; Procedure: Tumor biopsy

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00568490

IRB-10564

R01DE029672-01A1 (U.S. NIH Grant/Contract)

SU-11052007-801 (Other Identifier)

73995 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Full description

The endpoints of the study are

1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance.
2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
• Able to sign a Stanford IRB approved consent form

Exclusion criteria

• Refuse or unable to sign an IRB approved consent form.
• Refuse to be contacted in the future for follow up.